ow dose Atropine for Myopia control

Not Applicable

• Conditions: Health Condition 1: H521- Myopia

• Registration Number: CTRI/2019/09/021193
• Lead Sponsor: Centre for Sight

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Age: 6 to 18 years

2. Myopia >= 2.00 D (cycloplegic refraction; spherical equivalent) with or

without any astigmatism

3. The minimum increase in refractive error should be 0.75DS in less

than 6 months.

4. Provide written informed consent;

5. No prior or current treatment for preventing myopia progression

(bifocals / progressive addition lenses / orthokeratology)

6. Willingness and ability to follow all instructions and comply with

schedule for follow-up visits

Exclusion Criteria

1. Best corrected visual acuity < 6/18

2. Simple myopic/hyperopic astigmatism with 0 spherical refractive error (Pure astigmatism)

3. No prior or current treatment for preventing myopia progression (bifocals / progressive addition lenses / orthokeratology)

4. Ocular diseases like Retinal dystrophy, Retinopathy of prematurity, Corneal opacities, keratoconus, Ocular hypertension / Glaucoma

5. Prior intraocular surgery

6. Allergy to atropine eye drops

7. Lack of consent for participating in the study

8. Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome, Down syndrome, cardiac or significant respiratory diseases

9. Those lost to follow-ups, lack of 80% compliance to Atropine 0.01% eyedrops

10. In addition, the Investigator may exclude or discontinue any subject for any sound medical reason.

Study & Design

• Study Type: Interventional
• Study Design: Not specified